In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: Weyerhaeuser's current price exceeds its PERT-weighted fair value by nearly 20%, with valuation models largely indicating overvaluation except analyst targets and EV/EBITDA ranges. Financial health scores reflect weak profitability and growth amid high leverage, raising risk concerns. Monte Carlo outcomes show significant downside risk (77.8%) and high volatility, suggesting elevated investment uncertainty.